WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2018034492) COMPOSITION FOR PREVENTING, AMELIORATING, OR TREATING TH1-MEDIATED IMMUNE DISEASE, TH17-MEDIATED IMMUNE DISEASE, OR TH2-MEDIATED IMMUNE DISEASE COMPRISING PEDIOCOCCUS PENTOSACEUS AS ACTIVE INGREDIENT
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/034492 International Application No.: PCT/KR2017/008903
Publication Date: 22.02.2018 International Filing Date: 16.08.2017
IPC:
A61K 35/74 (2006.01) ,A61K 8/99 (2006.01) ,A61Q 19/00 (2006.01) ,A23K 10/16 (2016.01) ,A23L 33/135 (2016.01)
Applicants: KOREA FOOD RESEARCH INSTITUTE[KR/KR]; 62, Anyangpangyo-ro 1201beon-gil, Bundang-gu Seongnam-si Gyeonggi-do 13539, KR
Inventors: LEE, So Young; KR
SHON, Dong Hwa; KR
SHIN, Hee Soon; KR
JUNG, Sun Young; KR
DO, Jeong Ryong; KR
KWON, Da Ae; KR
BAE, Min Jung; KR
EOM, Ji Eun; KR
Agent: YOON, Dae Woong; KR
Priority Data:
10-2016-010362416.08.2016KR
Title (EN) COMPOSITION FOR PREVENTING, AMELIORATING, OR TREATING TH1-MEDIATED IMMUNE DISEASE, TH17-MEDIATED IMMUNE DISEASE, OR TH2-MEDIATED IMMUNE DISEASE COMPRISING PEDIOCOCCUS PENTOSACEUS AS ACTIVE INGREDIENT
(FR) COMPOSITION POUR LA PRÉVENTION, L'AMÉLIORATION OU LE TRAITEMENT D'UNE MALADIE IMMUNITAIRE À MÉDIATION PAR TH1, D'UNE MALADIE IMMUNITAIRE À MÉDIATION PAR TH17 OU D'UNE MALADIE IMMUNITAIRE À MÉDIATION PAR TH2 COMPRENANT DU PEDIOCOCCUS PENTOSACEUS EN TANT QUE PRINCIPE ACTIF
(KO) 페디오코쿠스 펜토사세우스를 유효성분으로 포함하는 TH1-매개 면역 질환, TH17-매개 면역 질환 또는 TH2-매개 면역 질환의 예방, 개선 또는 치료용 조성물
Abstract: front page image
(EN) The present invention relates to a composition for preventing, ameliorating, or treating a Th1-mediated immune disease, a Th17-mediated immune disease, or a Th2-mediated immune disease, the composition comprising Pediococcus pentosaceus as an active ingredient. The Pediococcus pentosaceus of the present invention induces regulatory T cells; regulates the ratio of the immune tolerant cytokine (IL-10; anti-inflammatory cytokine) to the immune activating cytokine (IL-12); and effectively controls a Th1-mediated immune disease, a Th17-mediated immune disease or a Th2-mediated immune disease by reducing Th1-related cytokines, Th17-related cytokines and Th2-related cytokines in the production of immunoglobulin E (IgE) and immune hypersensitive response, and therefore has an advantage that can be used as an anti-allergic composition and an anti-inflammatory composition.
(FR) La présente invention concerne une composition pour prévenir, améliorer ou traiter une maladie immunitaire à médiation par Th1, une maladie immunitaire à médiation par Th17, ou une maladie immunitaire à médiation par Th2, la composition comprenant du Pediococcus pentosaceus en tant que principe actif. Le Pediococcus pentosaceus selon la présente invention induit des lymphocytes T régulateurs; régule le rapport de la cytokine tolérante immunitaire (IL -10; cytokine anti-inflammatoire) à la cytokine d'activation immunitaire (IL -12); et contrôle efficacement une maladie immunitaire à médiation par Th1, une maladie immunitaire à médiation par Th17 ou une maladie immunitaire à médiation par Th2 par réduction des cytokines associées à Th1, des cytokines associées à Th17 et des cytokines associées à Th2 dans la production d'immunoglobuline E (IgE) et de la réponse hypersensible immunitaire et présente par conséquent un avantage qui peut être utilisé en tant que composition antiallergique et composition anti-inflammatoire.
(KO) 본 발명은 페디오코쿠스 펜토사세우스(Pediococcus pentosaceus)를 유효성분으로 포함하는 Th1-매개 면역 질환, Th17-매개 면역 질환 또는 Th2-매개 면역 질환의 예방, 개선 또는 치료용 조성물에 관한 것이다. 본 발명의 페디오코쿠스 펜토사세우스는 조절 T 세포를 유도하고, 면역 활성 사이토카인(IL-12)에 대한 면역 관용 사이토카인(IL-10; 항염증성 사이토카인)의 비율을 조절하며, 면역글로불린 E(IgE) 생성 및 면역과민반응 시 Th1-관련 사이토카인, Th17-관련 사이토카인 및 Th2-관련 사이토카인을 감소시킴으로써 Th1-매개 면역 질환, Th17-매개 면역 질환 또는 Th2-매개 면역 질환을 효과적으로 제어하는바 항알레르기성 조성물 및 항염증성 조성물로 사용이 가능한 이점이 있다.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Korean (KO)
Filing Language: Korean (KO)